AbbVie (ABBV) 8-K Guidance Including the Impact of Acquired IPR&D and Milestones Expense

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

(in millions, except per share data)	Quarter Ended December 31, 2022						Full-Year Ended December 31, 2022
	Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range				Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range
			Low		High				Low		High
Previously announced guidance excluding Q4 2022 acquired IPR&D and milestones expense	$	—	$	3.65	$	3.69	$	454	$	13.84	$	13.88
Q4 2022 acquired IPR&D and milestones expense	243		(0.14)		(0.14)		243		(0.14)		(0.14)
Guidance including Q4 2022 acquired IPR&D and milestones expense	$	243	$	3.51	$	3.55	$	697	$	13.70	$	13.74

    1